Article
MicroRNA-16 Restores Sensitivity to Tyrosine Kinase Inhibitors and Outperforms MEK Inhibitors in KRAS-Mutated Non-Small Cell Lung Cancer.
International journal of molecular sciences - 12 Dec 2021
Fanini Francesca, Bandini Erika, Plousiou Meropi, Carloni Silvia, Wise Petra, Neviani Paolo, Murtadha Mariam, Foca Flavia, Fabbri Francesco, Vannini Ivan, Fabbri Muller
Abstract excerpt
BACKGROUND: Non-small cell lung cancer (NSCLC) is the leading cause of cancer death worldwide. Chemotherapy, the treatment of choice in non-operable cases, achieves a dismal success rate, raising the need for new therapeutic options. In about 25% of NSCLC, the activating mutations of the KRAS oncogene define a subclass that cannot benefit from tyrosine kinase inhibitors (TKIs). The tumor suppressor miR-16 is...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.